PDCD1 and gastric cancer: Indeed, early clinical studies in GC using therapeutic antibodies targeting PD-1 have demonstrated promising results, with response rates of 22–27% of PD-L1-expressing GCs and 12% of PD-L1 negative GCs [2, 3].